| Borrowings |
Schedule
of borrowings
| | |
| | |
| | |
June 30, | |
| | |
December 31, | | |
December 31, | | |
2025 | |
| | |
2025 | | |
2025 | | |
(Audited) | |
| | |
US$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Current: | |
| | | |
| | | |
| | |
| - Bank overdraft | |
| 7,682 | | |
| 9,878 | | |
| 61,371 | |
| - Lease liabilities | |
| 1,570,074 | | |
| 2,018,958 | | |
| 2,059,748 | |
| - Bank borrowings | |
| 711,982 | | |
| 915,538 | | |
| - | |
| Borrowings Current | |
| 2,289,738 | | |
| 2,944,374 | | |
| 2,121,119 | |
| | |
| | | |
| | | |
| | |
| Non-current: | |
| | | |
| | | |
| | |
| - Lease liabilities | |
| 3,132,055 | | |
| 4,027,510 | | |
| 2,956,727 | |
| - Bank borrowings | |
| 1,564,621 | | |
| 2,011,946 | | |
| - | |
| Borrowings Non-Current | |
| 4,696,676 | | |
| 6,039,456 | | |
| 2,956,727 | |
| Borrowings | |
| 6,986,414 | | |
| 8,983,830 | | |
| 5,077,846 | |
The
breakdown of borrowings are as follows:
Schedule
of breakdown borrowings
| | |
| | |
| | |
June 30, | |
| | |
December 31, | | |
December 31, | | |
2025 | |
| | |
2025 | | |
2025 | | |
(Audited) | |
| | |
US$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Term loan
#1 | |
| 2,276,603 | | |
| 2,927,484 | | |
| - | |
| Term
loan | |
| 2,276,603 | | |
| 2,927,484 | | |
| - | |
Basel
Medical Group Ltd and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
the financial period ended December 31, 2025
| 15. |
Borrowings
(Continued) |
The
details of borrowings are as follows:
Schedule
of details borrowings
| Term loan | |
Facility
amount | | |
Effective
interest rate | |
Maturity
date |
| | |
| | |
% p.a. | |
|
| | |
| | | |
| |
|
| Term loan #1 | |
S$ | 3,000,000 | | |
Prime Rate + 4% | |
November 2028 |
| Term loan | |
Facility
amount | | |
Effective
interest rate | | |
Maturity
date |
| | |
| | |
% p.a. | | |
|
| | |
| | | |
| | | |
|
| Term loan #13 | |
S$ | 3,000,000 | | |
| 9 | % | |
November 2028 |
The
Group obtained a term loan facility from Green Link Digital Bank for working capital purposes. The loan bears interest at a floating
rate and is repayable by monthly instalments over a period of three years. The facility is secured by corporate guarantees from related
companies, a fixed deposit pledged with the bank, and charges over the Group’s bank accounts. The carrying amount of the loan as
at the reporting date was S$2,927,484 (US$2,276,603) (June 30, 2025: S$Nil).
Basel
Medical Group Ltd and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
the financial period ended December 31, 2025
| 15. |
Borrowings
(Continued) |
A
reconciliation of liabilities arising from financing activities is as follows:
Schedule
of reconciliation of liabilities arising from financing activities
| | |
Beginning
| | |
| | |
Proceed | | |
Non-cash
changes | | |
| | |
| |
| | |
of
financial | | |
Cash | | |
from
bank | | |
| | |
Accretion
of | | |
| | |
Fair value | | |
End of financial | |
| | |
year | | |
flows | | |
borrowings | | |
Addition | | |
interests | | |
Other | | |
reserve | | |
year | |
| | |
US$ | | |
US$ | | |
US$ | | |
US$ | | |
US$ | | |
US$ | | |
US$ | | |
US$ | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| December 31, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Bank overdraft | |
| 48,251 | | |
| (40,569 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 7,682 | |
| Lease liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| - Current | |
| 1,619,426 | | |
| (1,433,280 | ) | |
| - | | |
| 1,425,177 | | |
| 91,093 | | |
| - | | |
| - | | |
| 1,702,416 | |
| - Non-current | |
| 2,324,654 | | |
| - | | |
| - | | |
| 675,059 | | |
| - | | |
| - | | |
| - | | |
| 2,999,713 | |
| Bank borrowings | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| - Current | |
| - | | |
| (74,567 | ) | |
| 768,375 | | |
| - | | |
| 18,174 | | |
| - | | |
| - | | |
| 711,982 | |
| - Non-current | |
| - | | |
| - | | |
| 1,564,621 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,564,621 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
| 3,992,331 | | |
| (1,548,416 | ) | |
| 2,332,996 | | |
| 2,100,236 | | |
| 109,267 | | |
| - | | |
| - | | |
| 6,986,414 | |
Basel
Medical Group Ltd and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
the financial period ended December 31, 2025
| 15. |
Borrowings
(Continued) |
| | |
Beginning | | |
| | |
Proceed | | |
Non-cash
changes | | |
| | |
| |
| | |
of
financial | | |
Cash | | |
from
bank | | |
| | |
Accretion
of | | |
| | |
Fair
value | | |
End
of financial | |
| | |
year | | |
flows | | |
borrowings | | |
Addition | | |
interests | | |
Other | | |
reserve | | |
year | |
| | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| December
31, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Bank
overdraft | |
| 61,371 | | |
| (51,493 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 9,878 | |
| Lease
liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| -
Current | |
| 2,059,748 | | |
| (1,843,055 | ) | |
| - | | |
| 1,855,307 | | |
| 117,136 | | |
| - | | |
| - | | |
| 2,189,136 | |
| -
Non-current | |
| 2,956,727 | | |
| - | | |
| - | | |
| 900,605 | | |
| - | | |
| - | | |
| - | | |
| 3,857,332 | |
| Bank
borrowings | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| -
Current | |
| - | | |
| (95,886 | ) | |
| 988,054 | | |
| - | | |
| 23,370 | | |
| - | | |
| - | | |
| 915,538 | |
| -
Non-current | |
| - | | |
| - | | |
| 2,011,946 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 2,011,946 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
| 5,077,846 | | |
| (1,990,434 | ) | |
| 3,000,000 | | |
| 2,755,912 | | |
| 140,506 | | |
| - | | |
| - | | |
| 8,983,830 | |
Basel
Medical Group Ltd and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
the financial period ended December 31, 2025
| 15. |
Borrowings
(Continued) |
| | |
Beginning | | |
| | |
Proceed | | |
Non-cash
changes | | |
| | |
| |
| | |
of financial | | |
Cash | | |
from bank | | |
| | |
Accretion
of | | |
| | |
Fair value | | |
End of financial | |
| | |
year | | |
flows | | |
borrowings | | |
Addition | | |
interests | | |
Other | | |
reserve | | |
year | |
| | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| June 30, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Bank overdraft | |
| - | | |
| - | | |
| 61,371 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 61,371 | |
| Lease liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| - Current | |
| 28,500 | | |
| (1,096,308 | ) | |
| - | | |
| 4,524,209 | | |
| 114,966 | | |
| (1,511,619 | ) | |
| - | | |
| 2,059,748 | |
| - Non-current | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 50,087 | | |
| 2,906,640 | | |
| 2,956,727 | |
| Bank borrowings | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| - Current | |
| 2,677,856 | | |
| (6,766,838 | ) | |
| 4,000,000 | | |
| - | | |
| 88,982 | | |
| - | | |
| - | | |
| - | |
| - Non-current | |
| 1,583,434 | | |
| (1,583,434 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
| 4,289,790 | | |
| (9,446,580 | ) | |
| 4,061,371 | | |
| 4,524,209 | | |
| 203,948 | | |
| (1,461,532 | ) | |
| 2,906,640 | | |
| 5,077,846 | |
Basel
Medical Group Ltd and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
the financial period ended December 31, 2025
|
Schedule
of borrowings
| | |
2025 | | |
2025 | | |
2024 | |
| | |
US$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Current: | |
| | | |
| | | |
| | |
| - Bank overdraft | |
| 48,251 | | |
| 61,371 | | |
| - | |
| - Lease liabilities | |
| 1,619,426 | | |
| 2,059,748 | | |
| 28,500 | |
| - Bank borrowings | |
| - | | |
| - | | |
| 2,677,856 | |
| Borrowings Current | |
| 1,667,677 | | |
| 2,121,119 | | |
| 2,706,356 | |
| | |
| | | |
| | | |
| | |
| Non-current: | |
| | | |
| | | |
| | |
| - Lease liabilities | |
| 2,324,654 | | |
| 2,956,727 | | |
| - | |
| - Bank borrowings | |
| - | | |
| - | | |
| 1,583,434 | |
| Borrowings Non-Current | |
| 2,324,654 | | |
| 2,956,727 | | |
| 1,583,434 | |
| Borrowings | |
| 3,992,331 | | |
| 5,077,846 | | |
| 4,289,790 | |
The
breakdown of borrowings are as follows:
Schedule
of breakdown borrowings
| | |
2025 | | |
2025 | | |
2024 | |
| | |
US$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Term loan #1 | |
| - | | |
| - | | |
| 206,695 | |
| Term loan #2 | |
| - | | |
| - | | |
| 280,233 | |
| Term loan #3 | |
| - | | |
| - | | |
| 178,565 | |
| Term loan #4 | |
| - | | |
| - | | |
| 195,299 | |
| Term loan #6 | |
| - | | |
| - | | |
| 531,708 | |
| Term loan #7 | |
| - | | |
| - | | |
| 280,239 | |
| Term loan #9 | |
| - | | |
| - | | |
| 322,818 | |
| Term loan #10 | |
| - | | |
| - | | |
| 1,573,744 | |
| Term loan #11 | |
| - | | |
| - | | |
| 691,989 | |
| Term loan #12 | |
| - | | |
| - | | |
| - | |
| Term
loan | |
| - | | |
| - | | |
| 4,261,290 | |
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2025 and 2024
| 15. |
Borrowings (Continued) |
The
details of borrowings are as follows:
Schedule
of details borrowings
| Term loan | |
Facility
amount | |
Effective
interest rate | | |
Maturity date |
| | |
| |
| %
p.a. | | |
|
| | |
| |
| | | |
|
| Term loan #1 | |
S$600,000 | |
| 2.50 | % | |
October 2025 |
| Term loan #2 | |
S$1,000,000 | |
| 2.75 | % | |
October 2025 |
| Term loan #3 | |
S$600,000 | |
| 2.75 | % | |
November 2025 |
| Term loan #4 | |
S$700,000 | |
| 2.50 | % | |
November 2025 |
| Term loan #6 | |
S$1,400,000 | |
| 2.25 | % | |
April 2026 |
| Term loan #7 | |
S$1,000,000 | |
| 2.75 | % | |
October 2025 |
| Term loan #9 | |
S$850,000 | |
| 2.25 | % | |
April 2026 |
| Term loan #10 | |
S$600,000 | |
| 2.75 | % | |
November 2025 |
| | |
S$1,000,000 | |
| 3.00 | % | |
November 2025 |
| | |
S$500,000 | |
| 2.50 | % | |
March 2026 |
| | |
S$529,890 | |
| 1.53 | % | |
December 2035 |
| | |
S$501,670 | |
| 1.53 | % | |
December 2035 |
| Term loan #11 | |
S$400,000 | |
| 2.25 | % | |
January 2026 |
| | |
S$1,500,000 | |
| 2.50 | % | |
December 2025 |
| Term loan #12 | |
S$4,000,000 | |
| 4.30 | % | |
One-month term, upon maturity |
Term
loan #1 to #12 was fully settled during the financial year, and as at June 30, 2025, there are no outstanding bank borrowings.
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2025 and 2024
| 15. |
Borrowings (Continued) |
A
reconciliation of liabilities arising from financing activities is as follows:
Schedule
of reconciliation of liabilities arising from financing activities
| | |
Beginning of | | |
| | |
Proceed from | | |
Non-cash changes | |
|
Fair |
| |
End of | |
| | |
financial
year | | |
Cash
flows | | |
bank
borrowings | | |
Addition | | |
Accretion
of
interests | | |
Other | |
|
value
reserve |
| |
financial
year | |
| | |
| US$ | | |
| US$ | | |
| US$ | | |
| US$ | | |
| US$ | | |
| US$ | |
|
|
US$ |
| |
| US$ | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| June 30, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| Bank overdraft | |
| - | | |
| - | | |
| 48,251 | | |
| - | | |
| - | | |
| - | |
|
|
- |
| |
| 48,251 | |
| Lease liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| - Current | |
| 22,407 | | |
| (861,945 | ) | |
| - | | |
| 3,557,047 | | |
| 90,389 | | |
| (1,188,472 | ) |
|
|
- |
| |
| 1,619,426 | |
| - Non-current | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 39,380 | |
|
|
2,285,274 |
| |
| 2,324,654 | |
| Bank borrowings | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| - Current | |
| 2,105,398 | | |
| (5,320,259 | ) | |
| 3,144,901 | | |
| - | | |
| 69,960 | | |
| - | |
|
|
- |
| |
| - | |
| - Non-current | |
| 1,244,936 | | |
| (1,244,936 | ) | |
| - | | |
| - | | |
| - | | |
| - | |
|
|
- |
| |
| - | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| | |
| 3,372,741 | | |
| (7,427,140 | ) | |
| 3,193,152 | | |
| 3,557,047 | | |
| 160,349 | | |
| (1,149,092 | ) |
|
|
2,285,274 |
| |
| 3,992,331 | |
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2025 and 2024
| 15. |
Borrowings (Continued) |
| | |
Beginning of | | |
| | |
Proceed
from | | |
Non-cash changes | |
|
Fair |
| |
End
of | |
| | |
financial
year | | |
Cash flows | | |
bank
borrowings | | |
Addition | | |
Accretion
of
interests | | |
Other | |
|
value reserve |
| |
financial
year | |
| | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | | |
S$ | |
|
S$ |
| |
S$ | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
|
|
|
| |
| |
| June 30, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| Bank overdraft | |
| - | | |
| - | | |
| 61,371 | | |
| - | | |
| - | | |
| - | |
|
|
- |
| |
| 61,371 | |
| Lease liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| - Current | |
| 28,500 | | |
| (1,096,308 | ) | |
| - | | |
| 4,524,209 | | |
| 114,966 | | |
| (1,511,619 | ) |
|
|
- |
| |
| 2,059,748 | |
| - Non-current | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 50,087 | |
|
|
2,906,640 |
| |
| 2,956,727 | |
| Bank borrowings | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| - Current | |
| 2,677,856 | | |
| (6,766,838 | ) | |
| 4,000,000 | | |
| - | | |
| 88,982 | | |
| - | |
|
|
- |
| |
| - | |
| - Non-current | |
| 1,583,434 | | |
| (1,583,434 | ) | |
| - | | |
| - | | |
| - | | |
| - | |
|
|
|
| |
| - | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| | |
| 4,289,790 | | |
| (9,446,580 | ) | |
| 4,061,371 | | |
| 4,524,209 | | |
| 203,948 | | |
| (1,461,532 | ) |
|
|
2,906,640 |
| |
| 5,077,846 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| June 30, 2024 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| Liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| Lease liabilities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| - Current | |
| 566,039 | | |
| (553,000 | ) | |
| - | | |
| - | | |
| 15,461 | | |
| - | |
|
|
- |
| |
| 28,500 | |
| - Non-current | |
| 28,500 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (28,500 | ) |
|
|
- |
| |
| - | |
| Bank borrowings | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| - Current | |
| 3,223,150 | | |
| (2,517,707 | ) | |
| - | | |
| - | | |
| 160,777 | | |
| 1,811,636 | |
|
|
- |
| |
| 2,677,856 | |
| - Non-current | |
| 3,395,070 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,811,636 | ) |
|
|
- |
| |
| 1,583,434 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | |
| | |
| 7,212,759 | | |
| (3,070,707 | ) | |
| - | | |
| - | | |
| 176,238 | | |
| (28,500 | ) |
|
|
- |
| |
| 4,289,790 | |
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2025 and 2024
|